In Reply:
We appreciate your interest in our recent article entitled "Comparison of glomerular filtration rates calculated by different serum cystatin C-based equations in patients with chronic kidney disease". Traditionally, for most clinical circumstances, glomerular filtration rate (GFR) had been estimated from serum creatinine (SCr, eGFRcr). However, SCr concentration is influenced by non-GFR determinants, including muscle mass, diet, tubular secretion and extra-renal elimination by the gastrointestinal tract. Currently the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend initial use of SCr followed by a confirmatory test using cystatin C for evaluation of GFR when eGFRcr is thought to be inaccurate [1] . But recent published data suggested that, the combined creatinine-cystatin C based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is more useful as a confirmatory test than the equations based on SCr or cystatin C alone [2, 3] . Although cystatin C is less affected by racial differences, race is still an important determinant of GFR estimation [4] . Thus, race-specific modification is necessary before we accept the suggested guideline. In our study, we compared six-different cystatin C based eGFR equations and tried to find out more suitable cystatin C based eGFR equation in Korean CKD patients [5] . However, as you pointed out, we could not draw a conclusion because we did not measure the reference GFR. Thus, we fully agree with your suggestion that further studies are required to decide which of the equation is more suitable for the Korean CKD patients. In our study, we found that performance of serum cystatin C is quite different to that of SCr in patients with CKD stage 4 to 5 [5] , and we thought this finding might be associated with the extrarenal elimination of serum cystatin C [6] . However, in other large studies, this point has not been carefully evaluated [2, 3] . Thus, in our next study, we will focus more on the performance of eGFRcys in patients with CKD stage 4 to 5, and compare its accuracy to that of eGFRcr in those patients.
